California State Teachers Retirement System Acquires 16,773 Shares of Azenta, Inc. $AZTA

California State Teachers Retirement System increased its holdings in Azenta, Inc. (NASDAQ:AZTA) by 43.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,718 shares of the company’s stock after buying an additional 16,773 shares during the period. California State Teachers Retirement System’s holdings in Azenta were worth $1,177,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Caitong International Asset Management Co. Ltd increased its stake in Azenta by 2,067.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after acquiring an additional 765 shares during the period. Assetmark Inc. grew its holdings in shares of Azenta by 54.1% during the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after purchasing an additional 292 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Azenta by 44.9% in the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after purchasing an additional 385 shares during the period. Rockefeller Capital Management L.P. raised its stake in Azenta by 98.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock valued at $46,000 after purchasing an additional 689 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in Azenta by 141.2% in the fourth quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock valued at $53,000 after purchasing an additional 928 shares in the last quarter. 99.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AZTA shares. Needham & Company LLC increased their price objective on shares of Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings cut shares of Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $41.20.

Azenta Stock Up 1.1%

NASDAQ AZTA opened at $33.91 on Friday. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -12.29 and a beta of 1.37. Azenta, Inc. has a twelve month low of $15.93 and a twelve month high of $41.73. The stock has a fifty day simple moving average of $26.44 and a 200 day simple moving average of $25.24.

Azenta (NASDAQ:AZTA) last announced its earnings results on Tuesday, August 4th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. The business had revenue of $161.18 million for the quarter, compared to analysts’ expectations of $149.31 million. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.

Azenta Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.